Association of first trimester low PAPP-A levels with adverse pregnancy outcomes

Clinical and Experimental Obstetrics and Gynecology

Volumn 39, Issue 2, 2012, Pages 225-228

  Saruhan, Z ^a   Ozekinci, M ^a   Simsek, M ^a   Mendilcioglu, I ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

First trimester serum screening; PAPP A; Pregnancy complications

Indexed keywords

PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BIRTH WEIGHT; CASE CONTROL STUDY; DISEASE ASSOCIATION; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; HYDRAMNIOS; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL HYPERTENSION; MATERNAL SMOKING; NUCHAL TRANSLUCENCY MEASUREMENT; NULLIPARA; OLIGOHYDRAMNIOS; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PREMATURITY; PRENATAL CARE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; SMALL FOR DATE INFANT; UNIVERSITY HOSPITAL;

ADULT; BIRTH WEIGHT; DIABETES, GESTATIONAL; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MATERNAL AGE; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 84863630405     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Spencer K., Souter V., Tul N., Snijders R., Nicolaides K.H.: "A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A". Ultrasound Obstet. Gynecol., 1999, 13, 231.
2. Spencer K., Liao A.W., Skentou H., Cicero S., Nicolaides K.H.: "Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation". Prenat. Diagn., 2000, 20, 495.
3. Spencer K., Spencer C.E., Power M., Dawson C., Nicolaides K.H.: "Screening for Choromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience". BJOG, 2003, 110, 281.
4. Avgidou K., Papageorghiou A., Bindra R., Spencer K., Nicolaides K.H.: "Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies". Am. J. Obstet. Gynecol., 2005, 192, 1761.
5. Nicolaides K.H., Spencer K., Avgidou K., Faiola S., Falcon O.: "Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening". Ultrasound Obstet. Gynecol., 2005, 25, 221.
6. Breathnach F.M., Malone F.D., Lambert-Messerlian G.: "First and second trimester screening: detection of aneuploidies other than Down syndrome". Obstet. Gynecol., 2007, 110, 651.
7. Ball R.H., Caughey A.B., Malone F.D.: "First and second-trimester evaluation of risk for Down syndrome". Obstet. Gynecol., 2007, 110, 10.
8. Spencer K., Cowans N.J., Avgidou K., Molina F., Nicolaides K.H.: "First trimester biochemical markers of aneuploidy and the prediction of small for gestational age fetuses". Ultrasound Obstet. Gynecol., 2008, 31, 15.
9. Spencer K., Cowans N.J., Molina F., Kagan K.O., Nicolaides K.H.: "First trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery". Ultrasound Obstet. Gynecol., 2008, 31, 147.
10. Dugoff L., Hobbins J.C., Malone F.D.: "First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial)". Am. J. Obstet. Gynecol., 2004, 19, 1446.
11. Spencer K., Cowans N.J., Nicolaides K.H.: "Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia". Prenat. Diagn., 2008, 28, 7.
12. Smith G.C., Crossley J.A., Aitken D.A., Pell J.P., Cameron A.D., Connor J.M. et al.: "First trimester placentation and the risk of antepartum stillbirth". JAMA, 2004, 292, 2249.
13. Smith G.C., Shah I., Crossley J.A., Aitken D.A., Pell J.P., Nelson S.M. et al.: "Pregnancy-associated plasma protein A and alphafetoprotein and prediction of adverse perinatal outcome". Obstet. Gynecol., 2006, 107, 161.
14. Goetzl L., Krantz D., Simpson J.L., Silver R.K., Zachary J.M., Pergament E. et al.: "Pregnancy- associated plasma protein A, free beta hCG, nuchal translucency, and risk of pregnancy loss". Obstet. Gynecol., 2004, 104, 306.
15. Irwin J.C., Suen L.F., Martina N.A., Mark S.P., Guidice L.C.: "Role of the IGF system in trophoblast invasion and pre-eclampsia". Hum. Reprod., 1999, 14, 90.
16. Bonno M., Oxvig C., Kephart G.M.: "Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein messenger ribonucleic acid in placenta". Lab. Invest., 1994, 71, 560.
17. Lawrence J.B., Oxvig C., Overgaard M.T.: "The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein A". Proc. Natl. Acad. Sci., 1999, 96, 3149.
18. Conover C.A., Bale L.K., Overgaard M.T.: "Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development". Development, 2004, 131, 1187.
19. Krantz D., Goetzl L., Simpson J.L.: "Association of extreme first-trimester free human chorionic gonadotropin, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes". Am. J. Obstet. Gynecol., 2004, 191, 1452.
20. Smith G.C.S., Stenhouse E.J., Crossley J.A., Aitken D.A., Cameron A.D., Connor J.M.: "Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth". J. Clin. Endocrinol. Metab., 2002, 87, 1762.
21. Morssink L.P., Kornman L.H., Hallahan T.W.: "Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery". Prenat. Diagn., 1998, 18, 147.
22. Ong C.Y.T., Liao A.W., Spencer K., Munim S., Nicolaides K.H.: "First trimester maternal serum free (3-human chorionic gonadotrophin and pregnancy associated plasma protein A as predictor of pregnancy complication". Br. J. Obstet. Gynaecol., 2000, 107, 1265.
23. Yaron Y., Heifetz S., Ochshorm Y., Lehavi O., Orr-urtreger A.: "Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome". Prenat. Diagn., 2002, 22, 778.
24. Karagiannis G., Akolekar R., Sarquis R., Wright D., Nicolaides K.H.: "Prediction of small-for-gestation neomates from biophysical and biochemical markers at 11-13 weeks". Fetal Diagn. Ther., 2011, 29, 148.
25. Marttala J., Peuhkurinen S., Laitinen P., Gissler M., Nieminen P., Ryynanen M.: "Low maternal PAPP-A is associated with small-for-gestational age newborns and stillbirths". Acta Obstet. Gynecol., 2010, 89, 1226.